pentoxifylline has been researched along with Multiple Sclerosis in 11 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " To determine the immunoregulatory capacity of the phosphodiesterase inhibitor pentoxifylline (PTX), which is known to suppress the production of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), this drug was used in mitogen and antigen-stimulated lymphocyte cultures as well as in patients with multiple sclerosis." | 9.08 | Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. ( Bitsch, A; Börner, T; Broocks, A; Günther, A; Kitze, B; Martin, S; Poser, S; Rieckmann, P; Weber, F; Weber, T, 1996) |
| "Multiple sclerosis is probably mainly mediated by T-helper 1 (TH1)-lymphocytes." | 6.68 | A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. ( Adèr, HJ; Hartung, HP; Pflughaupt, KW; Polman, CH; Rep, MH; Scholten, PE; van Lier, RA; van Oosten, BW; von Blomberg, BM, 1996) |
| " To determine the immunoregulatory capacity of the phosphodiesterase inhibitor pentoxifylline (PTX), which is known to suppress the production of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), this drug was used in mitogen and antigen-stimulated lymphocyte cultures as well as in patients with multiple sclerosis." | 5.08 | Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. ( Bitsch, A; Börner, T; Broocks, A; Günther, A; Kitze, B; Martin, S; Poser, S; Rieckmann, P; Weber, F; Weber, T, 1996) |
| "As part of a multicenter treatment trial of vascular dementia, this method was then used to analyze MR films in 13 patients with vascular dementia who all had an MR study at baseline and at 1 year." | 2.68 | Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis. ( Broderick, JP; Dhawan, AP; Gaskill, M; Khoury, J; Narayan, S, 1996) |
| "Multiple sclerosis is probably mainly mediated by T-helper 1 (TH1)-lymphocytes." | 2.68 | A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. ( Adèr, HJ; Hartung, HP; Pflughaupt, KW; Polman, CH; Rep, MH; Scholten, PE; van Lier, RA; van Oosten, BW; von Blomberg, BM, 1996) |
| "Also, demyelination and glial scarring were significantly decreased in MMPI-treated mice with chronic relapsing EAE, as was central nervous system gene expression for TNF alpha and fasL." | 1.30 | Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. ( Cannella, B; Clements, JM; Gearing, AJ; Liedtke, W; Mazzaccaro, RJ; Miller, KM; Raine, CS; Wucherpfennig, KW, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (81.82) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broderick, JP | 1 |
| Narayan, S | 1 |
| Gaskill, M | 1 |
| Dhawan, AP | 1 |
| Khoury, J | 1 |
| Rieckmann, P | 3 |
| Weber, F | 3 |
| Günther, A | 3 |
| Martin, S | 1 |
| Bitsch, A | 2 |
| Broocks, A | 1 |
| Kitze, B | 1 |
| Weber, T | 1 |
| Börner, T | 1 |
| Poser, S | 3 |
| Friedman, JE | 1 |
| Zabriskie, J | 1 |
| Bourganskaia, E | 1 |
| van Oosten, BW | 1 |
| Rep, MH | 1 |
| van Lier, RA | 1 |
| Scholten, PE | 1 |
| von Blomberg, BM | 1 |
| Pflughaupt, KW | 1 |
| Hartung, HP | 1 |
| Adèr, HJ | 1 |
| Polman, CH | 1 |
| Polak, T | 1 |
| Kubuschok, B | 1 |
| Janovskaja, J | 1 |
| Liedtke, W | 1 |
| Cannella, B | 1 |
| Mazzaccaro, RJ | 1 |
| Clements, JM | 1 |
| Miller, KM | 1 |
| Wucherpfennig, KW | 1 |
| Gearing, AJ | 1 |
| Raine, CS | 1 |
| Myers, LW | 1 |
| Ellison, GW | 1 |
| Merrill, JE | 1 |
| El Hajjar, A | 1 |
| St Pierre, B | 1 |
| Hijazin, M | 1 |
| Leake, BD | 1 |
| Bentson, JR | 1 |
| Nuwer, MR | 1 |
| Tourtellotte, WW | 1 |
| Davis, P | 1 |
| Granger, D | 1 |
| Fahey, JL | 1 |
| Yoshikawa, M | 1 |
| Suzumura, A | 1 |
| Tamaru, T | 1 |
| Takayanagi, T | 1 |
| Sawada, M | 1 |
| Du, C | 1 |
| Cooper, JC | 1 |
| Klaus, SJ | 1 |
| Sriram, S | 2 |
| Bright, JJ | 1 |
1 review available for pentoxifylline and Multiple Sclerosis
| Article | Year |
|---|---|
Immunotherapy of inflammatory demyelinating diseases of the central nervous system.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; CD4-Positive T-Lymphocytes; Cerebrospinal F | 2001 |
5 trials available for pentoxifylline and Multiple Sclerosis
| Article | Year |
|---|---|
Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis.
Topics: Aspirin; Brain; Brain Ischemia; Dementia, Vascular; Double-Blind Method; Female; Humans; Magnetic Re | 1996 |
Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.
Topics: Autoimmune Diseases; Base Sequence; Cytokines; Humans; Intercellular Adhesion Molecule-1; Lymphocyte | 1996 |
A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Immune System; Male; Middle Aged; Multiple Sclero | 1996 |
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Base Sequence; Cells, Cultured; Chi-Square Distribution; Cytokines; Dose-Res | 1998 |
Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase.
Topics: Adult; Brain; Disease Progression; Dose-Response Relationship, Drug; Evoked Potentials, Visual; Huma | 1998 |
5 other studies available for pentoxifylline and Multiple Sclerosis
| Article | Year |
|---|---|
The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis.
Topics: Humans; Interferon-beta; Multiple Sclerosis; Pentoxifylline | 1996 |
A pilot study of pentoxifylline in multiple sclerosis.
Topics: Humans; Multiple Sclerosis; Pentoxifylline; Pilot Projects | 1996 |
Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.
Topics: Animals; Astrocytes; Autoimmune Diseases; Base Sequence; Benzyl Compounds; Chi-Square Distribution; | 1998 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamo | 1999 |
Amelioration of CR-EAE with lisofylline: effects on mRNA levels of IL-12 and IFN-gamma in the CNS.
Topics: Animals; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expressio | 2000 |